SciSparc is acquiring a comprehensive portfolio of patents and intellectual property rights for innovative endoscopic systems, including the MUSE system, from Xylo Technologies. This strategic move is intended to diversify SciSparc's portfolio beyond pharmaceuticals and expand its global market presence.

Through its majority-owned subsidiary NeuroThera Labs, the company has signed a binding term sheet to acquire a portfolio of patents, trademarks, and intellectual property for advanced endoscopic systems and medical cameras—including the MUSE system—from Xylo Technologies Ltd.

The MUSE system, a single-use device designed for transoral fundoplication, offers a minimally invasive solution for treating gastroesophageal reflux disease (GERD).

“Building on Xylo's successful commercialization in Greater China through a licensing and distribution agreement with a Shanghai-based medical instruments company in 2019, of which Xylo received $3 million up front, SciSparc seeks to replicate this proven model across high-growth territories, such as North America, Europe and Latin America, by pursuing similar exclusive partnerships with leading regional distributors to accelerate global commercialization and unlock substantial revenue streams,” the company said.

Under the terms of the agreement, SciSparc will acquire the full portfolio of patents, trademarks, know-how, and related IP associated with the MUSE system. In exchange, SciSparc will issue ordinary shares representing 19.99% of the company to Xylo upon closing, with the option to issue pre-funded warrants instead, at SciSparc’s discretion.

GERD device market was valued at $2.5 billion in 2024 and projected to reach $3.03 billion by 2030, according to a May 2025 report by MarkNtel Advisors. The market is expected to expand at a CAGR of 3.24% from 2025 to 2030.